Table 3.

Cox proportional hazards model predicting time to remission

Baseline characteristics	Univariate		Multivariable
	HR (95% CI)	p-value	HR (95% CI)	p-value
Sociodemographic
Female gender	0.71 (0.60–0.84)	<.0001	0.87 (0.70–1.09)	0.2256
Post-secondary education	1.26 (1.08–1.47)	0.0039	1.04 (0.87–0.70)	0.6744
Ever smoked	0.87 (0.75–1.02)	0.076	0.93 (0.77–1.12)	0.4269
RA family history	0.89 (0.74–1.07)	0.2176	0.87 (0.70–1.70)	0.1817
Disease characteristics
Positive rheumatoid factor	1.01 (0.85–1.19)	0.9182	0.94 (0.78–1.14)	0.5381
HAQ-DI	0.62 (0.55–0.69)	<.0001	0.71 (0.61–0.84)	<.0001
Morning stiffness (>30 min)	0.71 (0.61–0.83)	<.0001	0.89 (0.73–1.08)	0.2366
Joint erosion	0.94 (0.77–1.14)	0.5224	0.87 (0.70–1.08)	0.1954
DAS28	0.77 (0.72–0.82)	<.0001	0.88 (0.80–0.96)	0.0048
Extra-articular features	0.95 (0.78–1.14)	0.5534
Number of comorbidities	0.83 (0.77–0.88)	<.0001	0.88 (0.81–0.95)	0.0022
Osteoarthritis	0.93 (0.78–1.12)	0.4497
Treatment
Oral glucocorticoid	1.06 (0.86–1.30)	0.5800
Biologic or JAK inhibitor (time variant)	0.86 (0.71–1.03)	0.09	1.53 (0.63–3.69)	0.3485
LORA	0.83 (0.71–0.97)	0.0194	1.10 (0.90–1.34)	0.3593

CI confidence interval, DAS28 Disease Activity Score 28 joint count, JAK Janus kinase, HR hazard ratio, HAQ-DI health assessment questionnaire disability index, LORA late-onset rheumatoid arthritis, RA rheumatoid arthritis